Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
about
Venetoclax for the treatment of patients with chronic lymphocytic leukemia.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Venetoclax: First Global Approval.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
P2860
Q38685358-E38DE53F-8227-47F3-8E34-AEFF0098D7A0Q38766548-FE352886-2FE7-4862-B008-9E25C61FB02EQ38853500-1C143EDB-810F-4974-AC97-86DE96752F97Q39040977-BAAA98CF-BE4B-4375-85BB-9D20039C3AB5Q39137457-928C0E56-BDD5-4FF0-86C6-8A4CAB742268Q39177442-4216CB9C-78D7-4CB8-A6BA-329BCDEFDC98Q39200835-0E7C8175-D7DA-4BDB-8636-C8992CBE4294Q40537266-536BD837-91B7-4BD0-AF99-310C2851F758Q40597634-63976F99-32F1-4288-A35F-EF3F024B46B1Q45057327-C95E4ED1-3B03-4885-AAA6-38EB5B39CA65Q47553423-AAEB188B-E178-483A-B69C-571655A7E922Q47610956-465B3668-67B3-452B-AC59-54D30DB5A606Q48146110-42011F7C-146D-45F9-8FA0-68CB80EB5C84Q48257454-8F9AD76B-DD75-47E2-A12B-31DDE745995DQ50119590-E781F014-F1E6-4508-A655-5AD854A3BF1DQ51007604-59811FD6-955D-4295-95D9-E6C21E25F128Q51280033-6A4FC1FD-39E3-469A-8D44-C58C726D97DCQ51842580-9CE23BB9-1FF0-45F8-832A-02C62D0ADE1E
P2860
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.
@en
Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.
@nl
type
label
Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.
@en
Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.
@nl
prefLabel
Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.
@en
Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.
@nl
P2093
P2860
P356
P1476
Effect of Low- and High-Fat Me ...... First-in-Class BCL-2 Inhibitor
@en
P2093
Ahmed Hamed Salem
David Chien
Kevin J Freise
Martin Dunbar
Shekman L Wong
Silpa Nuthalapati
P2860
P304
P356
10.1002/JCPH.741
P577
2016-11-01T00:00:00Z